

[FDA Home](#)<sup>3</sup> [Drug Databases](#)<sup>4</sup> [Orange Book](#)<sup>5</sup>

### Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Patent and Exclusivity Search Results from query on Appl No 022410 Product 001 in the OB\_Rx list.

#### Patent Data

Appl No	Prod No	Patent No	Patent Expiration	Drug Substance Claim	Drug Product Claim	Patent Use Code	Delist Requested
<a href="#">N022410</a>	001	8017150	Feb 13, 2023		Y		
<a href="#">N022410</a>	001	8475832	Mar 26, 2030		Y	<a href="#">U - 1411</a>	
<a href="#">N022410</a>	001	8603514	Apr 3, 2024		Y	<a href="#">U - 1464</a>	

#### Exclusivity Data

Appl No	Prod No	Exclusivity Code	Exclusivity Expiration
<a href="#">N022410</a>	001	<a href="#">NDF</a>	Aug 30, 2013

#### Additional information:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. These patents may not be flagged with respect to other claims which may apply.

[View a list of all patent use codes](#)

[View a list of all exclusivity codes](#)

[Return to Electronic Orange Book Home Page](#)<sup>6</sup>

FDA/Center for Drug Evaluation and Research  
Office of Generic Drugs  
Division of Labeling and Program Support  
Update Frequency:

Orange Book Data - **Monthly**

Generic Drug Product Information & Patent Information - **Daily**

Orange Book Data Updated Through September 2014

Patent and Generic Drug Product Data Last Updated November 06, 2014

#### Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](#)
6. [../default.cfm](#)

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

[Accessibility Contact FDA Careers FDA Basics FOIA No Fear Act Site Map Transparency Website Policies](#)

U.S. Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Spring, MD 20993  
Ph. 1-888-INFO-FDA (1-888-463-6332)  
[Email FDA](#)



[For Government For Press](#)

[Combination Products Advisory Committees Science & Research Regulatory Information Safety Emergency Preparedness International Programs News & Events Training and Continuing Education Inspections/Compliance State & Local Officials Consumers Industry Health Professionals FDA Archive](#)

U.S. Department of **Health & Human Services**

#### Links on this page:

RB Ex. 2050

FDA Home<sup>3</sup> Drug Databases<sup>4</sup> Orange Book<sup>5</sup>  
**Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations**

Search results from the "OB\_Rx" table for query on "022410."

---

Active Ingredient: BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE  
Dosage Form;Route: FILM;SUBLINGUAL  
Proprietary Name: SUBOXONE  
Applicant: RECKITT BENCKISER  
Strength: EQ 2MG BASE;EQ 0.5MG BASE  
Application Number: N022410  
Product Number: 001  
Approval Date: Aug 30, 2010  
Reference Listed Drug: No  
RX/OTC/DISCN: RX  
TE Code:  
Patent and Exclusivity Info for this product: [View](#)

---

Active Ingredient: BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE  
Dosage Form;Route: FILM;SUBLINGUAL  
Proprietary Name: SUBOXONE  
Applicant: RECKITT BENCKISER  
Strength: EQ 8MG BASE;EQ 2MG BASE  
Application Number: N022410  
Product Number: 002  
Approval Date: Aug 30, 2010  
Reference Listed Drug: No  
RX/OTC/DISCN: RX  
TE Code:  
Patent and Exclusivity Info for this product: [View](#)

---

Active Ingredient: BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE  
Dosage Form;Route: FILM;SUBLINGUAL  
Proprietary Name: SUBOXONE  
Applicant: RECKITT BENCKISER  
Strength: EQ 4MG BASE;EQ 1MG BASE  
Application Number: N022410  
Product Number: 003  
Approval Date: Aug 10, 2012  
Reference Listed Drug: No  
RX/OTC/DISCN: RX

TE Code:

Patent and Exclusivity Info for this product: [View](#)

---

Active Ingredient:	BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE
Dosage Form;Route:	FILM;SUBLINGUAL
Proprietary Name:	SUBOXONE
Applicant:	RECKITT BENCKISER
Strength:	EQ 12MG BASE;EQ 3MG BASE
Application Number:	N022410
Product Number:	004
Approval Date:	Aug 10, 2012
Reference Listed Drug	Yes
RX/OTC/DISCN:	RX
TE Code:	
Patent and Exclusivity Info for this product:	<a href="#">View</a>

---

[Return to Electronic Orange Book Home Page<sup>6</sup>](#)

---

FDA/Center for Drug Evaluation and Research  
Office of Generic Drugs  
Division of Labeling and Program Support  
Update Frequency:

Orange Book Data - **Monthly**

Generic Drug Product Information & Patent Information - **Daily**

Orange Book Data Updated Through September 2014

Patent and Generic Drug Product Data Last Updated November 06, 2014

---

#### Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdomain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](#)
6. [../default.cfm](#)

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

[Accessibility Contact](#) [FDA Careers](#) [FDA Basics](#) [FOIA No Fear Act](#) [Site Map](#) [Transparency](#)  
[Website Policies](#)

U.S. Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Spring, MD 20993  
Ph. 1-888-INFO-FDA (1-888-463-6332)

Email FDA



For Government For Press

Combination Products Advisory Committees Science & Research Regulatory Information Safety  
Emergency Preparedness International Programs News & Events Training and Continuing  
Education Inspections/Compliance State & Local Officials Consumers Industry Health  
Professionals FDA Archive



Links on this page: